Is Lactoferrin more effective than inorganic iron in treating iron def anaemia in non-pregnant and if effective in pregnant women? 2 randomised trials

口服牛乳铁蛋白是一种新的、非传统的方法，可以在低收入环境下预防与母亲铁缺乏相关的低出生体重、早产和新生儿死亡。每年全球约有2000万低出生体重儿出生。低出生体重是由早产(出生早于预期的婴儿)或胎儿发育迟缓引起的。在围产期保健服务有限的国家，低出生体重和早产是新生儿死亡的主要原因。低出生体重儿死亡的可能性是重体重儿的20倍或更多，其中大部分死亡负担是早产。目前针对孕妇使用补铁剂(和叶酸)的范例往往失败，部分原因是副作用，这是在怀孕早期使用补充剂的一大障碍，这是缺铁妇女及其胎儿和未来新生儿的脆弱时期。此外，由于母体炎症和微量营养素缺乏阻碍了铁的有效利用，我们的方法将提供一种能够有效输送铁的产品，并且可以在怀孕早期的关键干预窗口期间服用，这为预防新生儿死亡提供了可能性。

Oral bovine lactoferrin is a novel, unconventional way to prevent low birthweight, preterm birth & neonatal deaths associated with maternal irondeficiency in low income settings. Each year about 20 million low birthweight babies are born worldwide. Low birthweight is caused by either preterm delivery (babies born earlier than expected) or fetal growth retardation. In countries where perinatal health services are limited, low birthweight and preterm birth are a major cause of neonatal deaths. Low birthweight babies are 20 or more times likely to die than heavier babies, with much of this mortality burden due to preterm birth. The current paradigm of using iron supplements (and folic acid) targeted at pregnant women often fails, in part because of the side effects, which are a strong barrier to use of the supplements early in pregnancy, a period of vulnerability for iron deficient women and their fetus and future newborn. And also because maternal inflammation and micronutrient deficiencies block effective utilization of iron Our approach will provide a product that will efficiently deliver iron and that can be taken early in pregnancy during a critical intervention window, which offers the potential to prevent neonatal deaths.